Abstract 7015: Valproic Acid Promotes Cardiac Regeneration and Improves Cardiac Function Following Myocardial Infarction
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.7015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Bijay Guragain und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Valproic acid (VPA), an FDA-approved histone deacetylase (HDAC) Inhibitor, is widely used in clinical practice, primarily for neurological and psychiatric disorders. However, its role in cardiology remains underexplored. Here, we investigate repurposing VPA as an agent to effect cardiac regeneration and repair following myocardial infarction.
Methods
In vitro , VPA was administered to 1-month-old cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). Cell proliferation markers (Ki67, Aurora kinase B [AuB], phospho-histone H3 [PH3]) were imaged with immunohistology and activation of the underlying signaling pathway involving pYAP, YAP, and FOXM1 was assessed with western blot. In vivo , VPA was intramyocardially administered to 3-month-old C57BL/6 mice hearts following permanent ligation of left anterior descending (LAD) coronary artery. Cardiac function was assessed using echocardiography at 1 and 4 weeks after myocardial infarction induction in 9 treated and 9 untreated control animals.
Results
In vitro , VPA significantly increased proliferation markers (Ki67, p=0.0003; AuB, p=0.0172; PH3, p=0.0026) in hiPSC-CMs (A-C) and induced an approximately two-fold increase in cell number after 2 weeks (1.07x10 5 vs 1.99x10 5 , p-value=0.0011). Western blot analysis showed that the proliferative response was associated with the activation of YAP signaling pathway and upregulation of FOXM1. In Vivo , VPA administration increased left ventricular ejection fraction (LVEF) and stroke volume (SV) relative to controls at both 1 week (LVEF: 27.88%±1.70% vs 20.49%±2.13%, p=0.0156; SV: 21.21±2.62 μL vs 14.76±1.18 μL, p=0.0392) and 4 weeks (LVEF: 34.40%±3.11% vs 25.64%±2.28%, p=0.0374; SV: 31.10±3.96 μL vs 21.54±1.25 μL, p=0.0348).
Conclusions
VPA enhances cardiomyocyte proliferation and improves cardiac function post-infarction, highlighting its potential as a therapeutic agent for cardiac regeneration.
Zitieren
APA
Guragain, B., Wu, Y., Zhang, H., Ye, L., Rogers, J., & Zhang, J. J. (2026). Abstract 7015: Valproic Acid Promotes Cardiac Regeneration and Improves Cardiac Function Following Myocardial Infarction. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.7015
Vancouver
Guragain B, Wu Y, Zhang H, Ye L, Rogers J, Zhang JJ. Abstract 7015: Valproic Acid Promotes Cardiac Regeneration and Improves Cardiac Function Following Myocardial Infarction. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.7015
BibTeX
@article{Guragain2026,
author = {Guragain, Bijay and Wu, Yalin and Zhang, Hanyu and Ye, Lei and Rogers, Jack and Zhang, Jianyi J},
title = {Abstract 7015: Valproic Acid Promotes Cardiac Regeneration and Improves Cardiac Function Following Myocardial Infarction},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.7015}
}
EUVIMED